CAS 165800-03-3|Linezolid
| Common Name | Linezolid | ||
|---|---|---|---|
| CAS Number | 165800-03-3 | Molecular Weight | 337.346 |
| Density | 1.3±0.1 g/cm3 | Boiling Point | 585.5±50.0 °C at 760 mmHg |
| Molecular Formula | C16H20FN3O4 | Melting Point | 176-1780C |
| MSDS | ChineseUSA | Flash Point | 307.9±30.1 °C |
| Symbol | GHS08 | Signal Word | Danger |
Names
| Name | linezolid |
|---|---|
| Synonym | More Synonyms |
Linezolid BiologicalActivity
| Description | Linezolid (PNU-100766) is a synthetic antibiotic used for the treatment of serious infections caused by Gram-positive bacteria that are resistant to several other antibiotics. |
|---|---|
| Related Catalog | Signaling Pathways >>Anti-infection >>BacterialResearch Areas >>Infection |
| References | [1]. Clemett D, Markham A. Linezolid. Drugs. 2000 Apr;59(4):815-27; discussion 828. [2]. Chiappini E, Conti C, Galli L et al. Clinical efficacy and tolerability of linezolid in pediatric patients: a systematic review. Clin Ther. 2010 Jan;32(1):66-88. [3]. Perry CM, Jarvis B. Linezolid: a review of its use in the management of serious gram-positive infections. Drugs. 2001;61(4):525-51. [4]. He MZ, Jiang YW, Cai C.Mechanisms and epidemiology of linezolid resistance in staphylococci.Zhonghua Jie He He Hu Xi Za Zhi. 2012 May;35(5):360-2. [5]. Karau MJ, Tilahun AY, Schmidt SM, Clark CR, Patel R, Rajagopalan G.Linezolid is Superior to Vancomycin in Experimental Pneumonia Caused by Superantigen-Producing Staphylococcus aureus in HLA class II Transgenic Mice.Antimicrob Agents Chemother. 2012 Jul 30. |
Chemical & Physical Properties
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Boiling Point | 585.5±50.0 °C at 760 mmHg |
| Melting Point | 176-1780C |
| Molecular Formula | C16H20FN3O4 |
| Molecular Weight | 337.346 |
| Flash Point | 307.9±30.1 °C |
| Exact Mass | 337.143799 |
| PSA | 71.11000 |
| LogP | 0.30 |
| Vapour Pressure | 0.0±1.6 mmHg at 25°C |
| Index of Refraction | 1.554 |
| InChIKey | TYZROVQLWOKYKF-ZDUSSCGKSA-N |
| SMILES | CC(=O)NCC1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1 |
| Storage condition | Store at RT |
Safety Information
| Symbol | GHS08 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H372 |
| Precautionary Statements | P314 |
| Target Organs | Bone |
| Hazard Codes | Xn: Harmful; |
| Risk Phrases | R20/21/22 |
| Safety Phrases | 36 |
| RIDADR | NONH for all modes of transport |
| RTECS | AC2720000 |
| HS Code | 2934999090 |
Customs
| HS Code | 2934999090 |
|---|---|
| Summary | 2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
Articles73
More Articles| Complete genome sequencing and comparative analysis of the linezolid-resistant Enterococcus faecalis strain DENG1. Arch. Microbiol. 196(7) , 513-6, (2014) Genome level analysis of bacterial strains provides information on genetic composition and resistance mechanisms to clinically relevant antibiotics. To date, whole genome characterization of linezolid... | |
| Gingival pain: an unusual side effect of ziprasidone. BMJ Case Rep. 2013 , doi:10.1136/bcr-2012-007577, (2013) The patient is a 52-year-old man with schizophrenia who developed severe, unremitting gingival pain after his ziprasidone dosage was increased from 80 to 120 mg. His physical examination and laborator... | |
| Once-weekly dalbavancin versus daily conventional therapy for skin infection. N. Engl. J. Med. 370(23) , 2169-79, (2014) Dalbavancin, a lipoglycopeptide antibiotic agent that is active against gram-positive pathogens, has a long plasma half-life, allowing for once-weekly dosing. DISCOVER 1 and DISCOVER 2 were identicall... |
Synonyms
| Linezolid |
| NDA 21-130 Zyvox |
| N-[[(5S)-3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide |
| Linezlid |
| Zyvoxid |
| Acetamide, N-(((5S)-3-(3-fluoro-4-(4-morpholinyl)phenyl)-2-oxo-5-oxazolidinyl)methyl)- |
| Zyvox |
| (S)-N-((3-(3-Fluoro-4-morpholinophenyl)-2-oxooxazolidin-5-yl)methyl)acetamide |
| N-{[(5S)-3-(3-Fluor-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamid |
| N-({(5S)-3-[3-Fluor-4-(morpholin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamid |
| Zyvoxam |
| Acetamide, N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- |
| N-[[(5S)-3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide |
| Zyvoxa |
| MFCD00937825 |
| N-({(5S)-3-[3-Fluoro-4-(morpholin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide |
| N-{[(5S)-3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide |
| N-{[(5S)-3-(3-fluoro-4-morpholin-4-ylphényl)-2-oxo-1,3-oxazolidin-5-yl]méthyl}acétamide |
| N-({(5S)-3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide |
